Implantable cardioverter defibrillator

Use in patients with no symptoms and at high risk

Joseph H. Levine, Theodore Waller, David Hoch, Steven Greenberg, Jeffrey Goldberger, Alan Kadish

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Twenty-seven patients with asymptomatic, nonsustained ventricular tachycardia whose evaluation suggested they were at high risk for sustained ventricular arrhythmias were treated with implantable cardioverter defibrillators. The option of conventional therapy (including the option of no therapy) was presented to each patient and rejected in favor of defibrillator implantation on an experimental basis. Eighteen patients had coronary artery disease and inducible sustained ventricular tachycardia, 8 had idiopathic dilated cardiomyopathy, and 1 had hypertrophic cardiomyopathy and a strong family history of sudden cardiac death. The mean ejection fraction was 27% ± 10%. Operative morbidity (3%) and mortality (3%) were low. Mean overall survival was 92% and 88% at 1 and 2 years, respectively. Sixteen (59%) of the 27 patients had appropriate defibrillator discharges during a mean follow-up of 35 ± 15 months. The mean time to first appropriate discharge was 18 ± 17 months, and mean follow-up after first discharge was 17 ± 20 months. In conclusion, implantable cardioverter defibrillator placement in high-risk patients without symptoms is a feasible approach that may have resulted in benefit in selected patients. Large-scale randomized trials currently under way will determine the risk/benefit ratio of this management approach.

Original languageEnglish (US)
Pages (from-to)59-65
Number of pages7
JournalAmerican Heart Journal
Volume131
Issue number1
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Implantable Defibrillators
Defibrillators
Ventricular Tachycardia
Hypertrophic Cardiomyopathy
Sudden Cardiac Death
Dilated Cardiomyopathy
Cardiac Arrhythmias
Coronary Artery Disease
Odds Ratio
Morbidity
Survival
Mortality
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Implantable cardioverter defibrillator : Use in patients with no symptoms and at high risk. / Levine, Joseph H.; Waller, Theodore; Hoch, David; Greenberg, Steven; Goldberger, Jeffrey; Kadish, Alan.

In: American Heart Journal, Vol. 131, No. 1, 01.01.1996, p. 59-65.

Research output: Contribution to journalArticle

Levine, Joseph H. ; Waller, Theodore ; Hoch, David ; Greenberg, Steven ; Goldberger, Jeffrey ; Kadish, Alan. / Implantable cardioverter defibrillator : Use in patients with no symptoms and at high risk. In: American Heart Journal. 1996 ; Vol. 131, No. 1. pp. 59-65.
@article{f7c4b01d8e3a4e839f5bf867e74d999e,
title = "Implantable cardioverter defibrillator: Use in patients with no symptoms and at high risk",
abstract = "Twenty-seven patients with asymptomatic, nonsustained ventricular tachycardia whose evaluation suggested they were at high risk for sustained ventricular arrhythmias were treated with implantable cardioverter defibrillators. The option of conventional therapy (including the option of no therapy) was presented to each patient and rejected in favor of defibrillator implantation on an experimental basis. Eighteen patients had coronary artery disease and inducible sustained ventricular tachycardia, 8 had idiopathic dilated cardiomyopathy, and 1 had hypertrophic cardiomyopathy and a strong family history of sudden cardiac death. The mean ejection fraction was 27{\%} ± 10{\%}. Operative morbidity (3{\%}) and mortality (3{\%}) were low. Mean overall survival was 92{\%} and 88{\%} at 1 and 2 years, respectively. Sixteen (59{\%}) of the 27 patients had appropriate defibrillator discharges during a mean follow-up of 35 ± 15 months. The mean time to first appropriate discharge was 18 ± 17 months, and mean follow-up after first discharge was 17 ± 20 months. In conclusion, implantable cardioverter defibrillator placement in high-risk patients without symptoms is a feasible approach that may have resulted in benefit in selected patients. Large-scale randomized trials currently under way will determine the risk/benefit ratio of this management approach.",
author = "Levine, {Joseph H.} and Theodore Waller and David Hoch and Steven Greenberg and Jeffrey Goldberger and Alan Kadish",
year = "1996",
month = "1",
day = "1",
doi = "10.1016/S0002-8703(96)90051-4",
language = "English (US)",
volume = "131",
pages = "59--65",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Implantable cardioverter defibrillator

T2 - Use in patients with no symptoms and at high risk

AU - Levine, Joseph H.

AU - Waller, Theodore

AU - Hoch, David

AU - Greenberg, Steven

AU - Goldberger, Jeffrey

AU - Kadish, Alan

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Twenty-seven patients with asymptomatic, nonsustained ventricular tachycardia whose evaluation suggested they were at high risk for sustained ventricular arrhythmias were treated with implantable cardioverter defibrillators. The option of conventional therapy (including the option of no therapy) was presented to each patient and rejected in favor of defibrillator implantation on an experimental basis. Eighteen patients had coronary artery disease and inducible sustained ventricular tachycardia, 8 had idiopathic dilated cardiomyopathy, and 1 had hypertrophic cardiomyopathy and a strong family history of sudden cardiac death. The mean ejection fraction was 27% ± 10%. Operative morbidity (3%) and mortality (3%) were low. Mean overall survival was 92% and 88% at 1 and 2 years, respectively. Sixteen (59%) of the 27 patients had appropriate defibrillator discharges during a mean follow-up of 35 ± 15 months. The mean time to first appropriate discharge was 18 ± 17 months, and mean follow-up after first discharge was 17 ± 20 months. In conclusion, implantable cardioverter defibrillator placement in high-risk patients without symptoms is a feasible approach that may have resulted in benefit in selected patients. Large-scale randomized trials currently under way will determine the risk/benefit ratio of this management approach.

AB - Twenty-seven patients with asymptomatic, nonsustained ventricular tachycardia whose evaluation suggested they were at high risk for sustained ventricular arrhythmias were treated with implantable cardioverter defibrillators. The option of conventional therapy (including the option of no therapy) was presented to each patient and rejected in favor of defibrillator implantation on an experimental basis. Eighteen patients had coronary artery disease and inducible sustained ventricular tachycardia, 8 had idiopathic dilated cardiomyopathy, and 1 had hypertrophic cardiomyopathy and a strong family history of sudden cardiac death. The mean ejection fraction was 27% ± 10%. Operative morbidity (3%) and mortality (3%) were low. Mean overall survival was 92% and 88% at 1 and 2 years, respectively. Sixteen (59%) of the 27 patients had appropriate defibrillator discharges during a mean follow-up of 35 ± 15 months. The mean time to first appropriate discharge was 18 ± 17 months, and mean follow-up after first discharge was 17 ± 20 months. In conclusion, implantable cardioverter defibrillator placement in high-risk patients without symptoms is a feasible approach that may have resulted in benefit in selected patients. Large-scale randomized trials currently under way will determine the risk/benefit ratio of this management approach.

UR - http://www.scopus.com/inward/record.url?scp=0030031681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030031681&partnerID=8YFLogxK

U2 - 10.1016/S0002-8703(96)90051-4

DO - 10.1016/S0002-8703(96)90051-4

M3 - Article

VL - 131

SP - 59

EP - 65

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 1

ER -